Coaching with Ketamine Therapy for Depression
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is being conducted at Massachusetts General Hospital (MGH) to explore whether adding psychedelic coaching can enhance the effects of ketamine or esketamine maintenance treatment in individuals with treatment-resistant depression (TRD). The investigators are currently enrolling participants who are receiving ongoing maintenance intravenous (IV) ketamine or intranasal esketamine (Spravato) treatment at the MGH Ketamine Clinic. Participation in the study will involve adding coaching sessions to your existing ketamine maintenance treatment.
Who Is on the Research Team?
Maren Nyer, PhD
Principal Investigator
Massachusetts General Hospital and Harvard Medical School
Franklin King, MD
Principal Investigator
Massachusetts General Hospital and Harvard Medical School
David Mischoulon, MD/PhD
Principal Investigator
Massachusetts General Hospital and Harvard Medical School
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ongoing maintenance intravenous (IV) ketamine or intranasal esketamine (Spravato) treatment with adjunctive psychedelic coaching sessions
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Psychedelic Integration Coaching
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
Fireside Project
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.